HOME
ABOUT
LOG-IN
SEARCH BY
Search Results
Search Terms:Company Category= Life Sciences Company-Imaging| Avid Radiopharmaceuticals 3624 Market Street 5th Floor Philadelphia, PA 19104 215-966-6208 Nan Kruzik kruzik@avidrp.com www.avidrp.com Avid Radiopharmaceuticals is a product-focused molecular imaging company. Avid has developed proprietary radiopharmaceuticals to image amyloid plaques and is testing these agents in clinical trials for the detection of Alzheimer’s. Avid is also developing novel agents to image pathology in other types of dementia and Parkinson’s. These agents have the potential to revolutionize early diagnosis and monitoring of neurodegenerative diseases. |
| Capital Biosciences, Inc. 9700 Great Seneca Hwy Suite 247 Rockville, MD 20850 240-207-2314 Gary Veytsman techsupport@capitalbiosciences.com http://www.capitalbiosciences.com Capital Biosciences, Inc. offers innovative tools and solutions for life sciences researchers worldwide, including: fresh viable, frozen, and FFPE human tissues; cell immortalization products and services; and fluorescent in vivo imaging products. |
| Immunicon Corporation 3401 Masons Mill Road Suite 100 Huntingdon Valley, PA 19006 215-830-0777 Byron D. Hewett, President and CEO BHewett@Immunicon.com www.immunicon.com Immunicon is developing and commercializing diagnostic and research products for rare cell analysis and molecular research, with an initial focus on cancer. Our instruments and reagents are used to capture, count and characterize rare cells including circulating tumor cells in cancer patients or circulating endothelial cells, which are elevated in a variety of diseases. |
| MicroMRI, Inc. 1429 Walnut Street Suite 1102 Philadelphia, PA 19102 215-564-1002 Maura Hannigan-Pierce mpierce@micromri.com www.MicroMRI.com MicroMRI specializes in commercializing highly-accurate, non-invasive biomarkers derived from next-generation imaging technology for debilitating diseases such as osteoporosis and osteoarthritis. MicroMRI then works with the medical community to validate and legitimize the biomarkers as surrogate endpoints for drug research, clinical studies and therapeutic treatment. The company’s intends to build a portfolio of imaging-based surrogate endpoints. |
| Molecular Devices 402 Boot Road Downingtown, PA 19335 800-635-5577 Mike Duvinski Mike.Duvinski@moldev.com www.MolecularDevices.com Molecular Devices Corporation is a leading supplier of high-performance bioanalytical measurement systems that accelerate and improve drug discovery and other life sciences research. Our systems and consumables enable pharmaceutical and biotechnology companies to leverage advances in genomics, proteomics and parallel chemistry by facilitating the high-throughput and cost-effective identification and evaluation of drug candidates. |
| NanoScan Imaging, LLC 2250 Berks Road Lansdale, PA 19446 215-699-1703 Don Skerrett, CEO DSkerrett@aol.com www.nanoscanimaging.com NanoScan Imaging is managing the clinical development of N1177, a nanoparticle diagnostic pharmaceutical expected to improve x-ray computed tomography (“CT”)’s ability to diagnose and manage various forms of cancer and cardiovascular disease. NSI plans to take N1177 through proof of concept clinical studies and then sell it to a strategic partner to complete its development and commercialization. |
| Real Time X, Corp. 1510 Cecil B. Moore Avenue Suite 301 Philadelphia, PA 19121 267-979-9250 Daniel Uzbelger Feldman uzbelger@realtimedentistry.com www.realtimedentistry.com RTXC’s mission is to revolutionize dentistry by delivering innovative, top-quality, real-time imaging solutions that will improve professionals’ ability to diagnose disease, “see” their procedures during performance, save working time, reduce procedural errors and provide increased safety and better care to their patients. |